The ROCA Test is a blood test that determines the risk of a woman having ovarian cancer. The test is intended for women over 35 with a mutation in the BRCA1 or BRCA2 gene that confers a high risk of developing ovarian cancer.
Women with a BRCA1 or BRCA2 gene mutation are generally recommended to consider preventative surgery (removal of both ovaries and fallopian tubes). However, this results in early menopause and affects fertility. For women who choose to delay this procedure, the ROCA Test may be a helpful option.
The ROCA Test is not yet available the NHS but can be obtained via privately through one of our expert clinicians offering ROCA Care. Current clinics are located in Cardiff and London.
The ROCA Test is intended for women who are over 35 years old, have tested positive for BRCA1 or BRCA2 gene mutation and wish to delay risk reducing surgery.
Any woman interested in having survellance using the ROCA Test must have a consultation with a clinician, so that she can understand the latest clinical evidence, and gain an informed view on the benefits and risks of using the ROCA Test. During the consultation, the clinician will assess your risk of ovarian cancer and your suitability for the test. Anyone interested should please get in touch with us at contact us and we can find a clinician near you.
In November 2022, the Journal of Medical Genetics published a paper that presented the results of a pilot national ovarian cancer surveillance programme using the ROCA Test, for women with alterations in the BRCA1 and BRCA2 genes.Read more
In November 2022, the Journal of Medical Genetics published a paper that presents the results of a pilot national surveillance programme using the ROCA Test, for women with alterations in the BRCA1 and BRCA2 genes. The study was called ALDO, meaning ‘Avoiding Late Diagnosis of Ovarian cancer’.Read more